Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?

Polaris Capital Management , an investment management company, released its second-quarter 2026 investor letter for "Global Equity Strategy". The letter can be downloaded here . Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% during the quarter, compared to a 13.90% return for the MSCI World Index, gross dividends reinvested. The Composite remained ahead for the year-to-date period through June 30, 2026, gaining 19.95% versus 9.94% for the benchmark, driven by strong performance from IT holdings, particularly AI-related companies and memory semiconductor suppliers. Please review the Fund's top five holdings to gain insights into its key selections for 2026.

In its second-quarter 2026 investor letter, Polaris Global Equity Strategy highlighted Cytokinetics, Incorporated (NASDAQ: CYTK ). Cytokinetics, Incorporated (NASDAQ:CYTK) is a US-based biopharmaceutical company that focuses on developing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases. On September 22, 2026, Cytokinetics, Incorporated (NASDAQ:CYTK) closed at $67.59 per share. Over the past month, Cytokinetics, Incorporated (NASDAQ:CYTK) declined 14.66%, and its shares gained 39.97% over the past 52 weeks. Cytokinetics, Incorporated (NASDAQ:CYTK) has a market capitalization of $9.4 billion, and its stock has traded within a 52-week range of $47.22 to $88.31.

Polaris Global Equity Strategy stated the following regarding Cytokinetics, Incorporated (NASDAQ:CYTK) in its Q2 2026 investor letter:

"We added Cytokinetics, Incorporated (NASDAQ:CYTK) to our portfolio, a U.S. biopharma company with FDA approval for Myqorzo for hypertrophic cardiomyopathy; Myqorzo is seen as superior to Bristol Myers Squibb's Camzyos, offering better symptom relief with simpler dosing."

Cytokinetics, Incorporated (NASDAQ:CYTK) is not on our list of the 40 Most Popular Stocks Among Hedge Funds . As per our database, 78 hedge fund portfolios held Cytokinetics, Incorporated (NASDAQ:CYTK) at the end of the second quarter which was 67 in the previous quarter. While we acknowledge the potential of Cytokinetics, Incorporated (NASDAQ:CYTK) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .